Plant ID: NPO16326
Plant Latin Name: Scopolia parviflora
Taxonomy Genus: Scopolia
Taxonomy Family: Solanaceae
NCBI TaxonomyDB:
258455
Plant-of-the-World-Online:
n.a.
Romania; South Korea
TSHR; | |
CHRM1; CHRM2; CHRM3; CHRM5; | |
BLM; AKR1B1; GFER; HSD17B10; AKR1B10; ALDH1A1; POLB; | |
CA2; CA1; CA12; CA9; CA13; CA7; | |
CASP1; CASP7; | |
TP53; NFKB1; |
Cytochrome P450 Enzymes: | CYP1A2; |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
Small molecule receptor (family A GPCR) | CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 | CHEMBL211 |
Small molecule receptor (family A GPCR) | CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 | CHEMBL245 |
Small molecule receptor (family A GPCR) | CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 | CHEMBL2035 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.962E-15 | 1.516E-10 | CA1, CA12, CA13, CA2, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.667E-12 | 1.936E-08 | CA1, CA12, CA13, CA2, CA7, CA9 |
BP | GO:0050896; response to stimulus | GO:0007197; adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway | 7.629E-12 | 3.323E-08 | CHRM1, CHRM2, CHRM3, CHRM5 |
MF | GO:0060089; molecular transducer activity | GO:0016907; G-protein coupled acetylcholine receptor activity | 7.629E-12 | 3.323E-08 | CHRM1, CHRM2, CHRM3, CHRM5 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.606E-12 | 3.486E-08 | CA1, CA12, CA13, CA2, CA7, CA9 |
BP | GO:0050896; response to stimulus | GO:0007207; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway | 2.287E-11 | 7.114E-08 | CHRM1, CHRM2, CHRM3, CHRM5 |
BP | GO:0023052; signaling | GO:0007271; synaptic transmission, cholinergic | 2.632E-08 | 4.094E-05 | CHRM1, CHRM2, CHRM3, CHRM5 |
BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 1.150E-06 | 1.252E-03 | BLM, CA2, CA9, CASP1, CASP7, CYP1A2, NFKB1, TP53 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.656E-06 | 2.314E-03 | BLM, CA1, CA12, CA13, CA2, CA7, CA9, TP53 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.066E-06 | 3.279E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0004435; phosphatidylinositol phospholipase C activity | 4.234E-06 | 3.292E-03 | CHRM1, CHRM3, CHRM5 |
BP | GO:0032501; multicellular organismal process | GO:0046541; saliva secretion | 1.353E-05 | 7.964E-03 | CHRM1, CHRM3 |
BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 1.643E-05 | 9.412E-03 | AKR1B1, BLM, CA9, CASP1, NFKB1, POLB, TP53 |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.892E-05 | 1.056E-02 | AKR1B1, AKR1B10, ALDH1A1 |
CC | GO:0044456; synapse part | GO:0043679; axon terminus | 3.716E-05 | 1.647E-02 | CHRM1, CHRM2, CHRM3 |
CC | GO:0045202; synapse | GO:0032279; asymmetric synapse | 3.781E-05 | 1.647E-02 | CHRM2, CHRM3 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 6.387E-05 | 2.398E-02 | CA2, CA9, CHRM3, TSHR |
CC | GO:0044456; synapse part | GO:0045211; postsynaptic membrane | 1.041E-04 | 3.361E-02 | CHRM1, CHRM2, CHRM3, CHRM5 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.395E-14 | 1.423E-12 | CA12, CA1, CA2, CA7, CA9, CA13 |
09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 7.335E-06 | 3.741E-04 | CHRM2, CHRM3, CHRM1, CHRM5 |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.348E-05 | 4.584E-04 | CHRM2, CHRM3, CHRM1, CHRM5, TSHR |
09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 3.352E-05 | 8.547E-04 | CASP7, CASP1, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 4.915E-05 | 1.003E-03 | CHRM2, CHRM3, CHRM1, CHRM5 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 7.261E-05 | 1.227E-03 | CHRM2, CHRM1, NFKB1, TSHR |
09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 9.620E-05 | 1.227E-03 | CHRM2, CHRM3, CHRM1, CHRM5 |
09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 8.499E-05 | 1.227E-03 | CASP7, CASP1, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 5.690E-04 | 5.223E-03 | CHRM2, CHRM1, TP53, NFKB1 |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 5.365E-04 | 5.223E-03 | CASP7, TP53, NFKB1 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 5.396E-04 | 5.223E-03 | AKR1B10, AKR1B1 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00040 | Pentose and glucuronate interconversions | 7.783E-04 | 6.106E-03 | AKR1B10, AKR1B1 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00051 | Fructose and mannose metabolism | 6.144E-04 | 5.223E-03 | AKR1B10, AKR1B1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
K00-K95: Diseases of the digestive system | Colitis | K50-K52 | CHRM5; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | CHRM1; CHRM5; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | CHRM1; CHRM2; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CHRM3; |
NA: NA | Addiction | NA | CHRM2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | CHRM1; |
NA: NA | Abdominal stomach pain | NA | CHRM1; |
NA: NA | Excessive sweating | NA | CHRM1; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM1; CHRM5; |
C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnosing bronchial hyperreactivity | W88 | CHRM3; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | CHRM2; |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | CHRM1; CHRM2; |
C00-D49: Neoplasms | Cancer | C00-C96 | TP53; CA9; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Postoperative nausea and vomiting | R11 | CHRM3; |
J00-J99: Diseases of the respiratory system | Obstructive lung diseases | J40-J44, J47 | CHRM3; |
NA: NA | Functional bowel syndrome | NA | CHRM1; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
L00-L99: Diseases of the skin and subcutaneous tissue | Seborrhea | L21 | CHRM3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRM1; CHRM5; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | CHRM2; |
A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM1; CHRM5; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
NA: NA | Schizoaffective disorders | NA | CHRM1; |
G00-G99: Diseases of the nervous system G00-G99 | Central and peripheral nervous diseases | G96.9 | CHRM5; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | CHRM2; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CHRM1; CHRM3; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; CA9; |
NA: NA | Spasms | NA | CHRM3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Sjogren's syndrome | M35.0 | CHRM3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | CHRM5; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Stabilize muscle contractions | M00-M99 | CHRM2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1; |
G00-G99: Diseases of the nervous system G00-G99 | Brain diseases | G00-G99 | CHRM5; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | CHRM2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1; |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | CHRM3; |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | CHRM1; CHRM5; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CHRM1; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | CHRM5; |
NA: NA | Dystonia | NA | CHRM1; |
N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | CHRM1; CHRM2; CHRM3; CHRM5; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRM1; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | CHRM1; CHRM3; CHRM5; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | CHRM1; CHRM2; CHRM3; |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | CHRM5; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Amnesia | F04 | CHRM5; |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
N00-N99: Diseases of the genitourinary system | Overactive bladder | N32.81 | CHRM3; |
C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM1; CHRM3; |